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Summary
Context and Objective Nonfunctioning pituitary adenomas
(NFPAs) are the most common subtype of pituitary tumour.
Hypopituitarism is observed in NFPAs due to tumour- or treat-
ment-related factors and may increase mortality risk. Here, we
analysed the associations of hypopituitarism, hormone replace-
ment and mortality in a large NFPA cohort derived from two
large European centres.
Design, Setting and Participants Case note review of all
patients treated for NFPA in University Hospitals Birmingham
and Beaumont Hospital Dublin between 1999 and 2014 was per-
formed.
Main Outcome Measures Clinical presentation, treatment
strategies, pituitary function and vitality status were recorded in
each patient. A multivariate Cox regression model was used to
examine the association between hypopituitarism, hormone
replacement and premature mortality.
Results A total of 519 patients were included in the analysis.
Median duration of follow-up was 70 years (05–43). A total of
81 deaths were recorded (156%). On multivariate analysis,
adrenocorticotropic hormone (ACTH) and gonadotropin (Gn)
deficiencies were associated with an increased relative risk of
death (OR 226, 95% CI 115–447, P = 001 and OR 256, 95%
CI 110–596, P = 001, respectively). Increased hydrocortisone
(HC) (P-trend = 002) and lower levothyroxine (LT4) doses (P-
trend = 003) were associated with increased risk of death.
Mortality increased with the degree of pituitary failure observed
(P-trend = 004).
Conclusion ACTH and gonadotropin-deficient patients have
higher mortality rates compared to those with intact hormonal
axes. Excessive HC and suboptimal LT4 replacement may also
increase risk of death. Complex associations between hormone
deficiency and replacement underpin the increased mortality risk
in NFPA patients.
(Received 9 February 2016; returned for revision 9 May 2016;
finally revised 31 May 2016; accepted 17 June 2016)
Introduction
Nonfunctioning pituitary adenomas (NFPAs) are benign
tumours which do not cause clinical syndromes of pituitary hor-
mone hypersecretion.1 They constitute one-third of all pituitary
neoplasms2,3 and have a prevalence of approximately 22 cases
per 100 000 population.4 Postoperative radiotherapy (RT) is
effective at reducing the risk of tumour regrowth after
transsphenoidal surgery (TSS).5,6 However, patients with NFPA
are at significant risk of hypopituitarism, which may be sec-
ondary to the tumour itself or a sequela of its treatment. Pitu-
itary irradiation confers a substantial risk of hypopituitarism7,8
and has been associated, directly or indirectly, with increased
mortality.9,10 A causal link between hypopituitarism and mortal-
ity has been extensively reported, but many studies are described
in the context of syndromes of pituitary hormone hypersecre-
tion, such as acromegaly, Cushing’s disease and prolactinoma.11–13
Functional pituitary tumours introduce the confounding vari-
able of exposure to hormone excess, often associated with
adverse cardiometabolic risk, as observed in acromegaly or
hypercortisolism.
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Such confounders are not applicable in the setting of NFPAs,
where hypopituitarism is highly prevalent but where patients
have not had cumulative exposure to hormone hypersecretion.
Mortality data in NFPA patients with hypopituitarism have been
conflicting. A recent large Swedish population-based study
found that excess deaths were observed only in female patients
with hypopituitarism.14 However, data on the severity of pitu-
itary failure, or on individual pituitary axis deficiencies, were
not available, and therefore, independent effects of pituitary axis
disruption could not be delineated. An older Danish study of
160 patients with NFPA also found evidence of increased mor-
tality risk in women, but not in men, with hypopituitarism.15
The study by Tomlinson et al.16 included a subset of 573
hypopituitary patients treated for NFPA; only gonadotropin
(Gn) deficiency was associated with increased mortality in both
sexes.
Irradiation of pituitary tumours, either prophylactically after
surgery or reactively after tumour recurrence, also confounds
the study of hypopituitarism and mortality. RT itself has been
independently associated with increased mortality risk in the
treatment of both acromegaly and NFPA,9,11 with the higher
death rate largely attributable to cerebrovascular disease. How-
ever, an independent association between RT and mortality in
NFPA has not been consistently replicated across studies, and
both the Tomlinson study and the Dutch study of van Vars-
seveld found no increase in mortality between irradiated and
nonirradiated patients.16,17 Further confounders in this area
include treatment-associated effects on mortality; overzealous
hydrocortisone (HC) replacement in patients with adrenocorti-
cotropic hormone (ACTH) deficiency has been associated with
increased mortality, both in NFPA and acromegaly.11,18 Growth
hormone (GH) and testosterone replacement may reduce mor-
tality in GH and Gn deficiencies, respectively.16,19 There are few
published data on the impact of levothyroxine (LT4) dosages on
mortality in thyroid-stimulating hormone (TSH) deficiency.
Moreover, comprehensive studies on the impact of hypopitu-
itarism and treatment of multiple coexistent hormone deficien-
cies are sparse in NFPA.
Nonfunctioning pituitary adenomas are an attractive disease
model to study these associations, largely due to the ability to
exclude the confounding effects of hormone hypersecretion. In
this study, we hypothesized that NFPA patients with hypopitu-
itarism have an increased risk of mortality compared to those
with normal pituitary function, independent of other potential
risk factors such as pituitary irradiation or age at diagnosis; we
also hypothesized that treatment of individual hormone deficien-
cies may itself independently impact on survival. To test these
hypotheses, we performed a collaborative European retrospective
analysis of a large NFPA cohort, derived from two tertiary refer-
ral centres in the UK and Republic of Ireland, and collectively
analysed the effects of hypopituitarism on long-term survival.
Patient mortality data were compared across a spectrum of
increasing severity of hypopituitarism. We also compared sur-
vival data on patients with individual hormone deficiencies to
those with intact function of the corresponding pituitary hor-
mone axis. Lastly, we performed a comprehensive assessment of
the impact of pituitary hormone replacement on mortality risk.
For patients with GH and Gn deficiencies, mortality risk was
compared between treated and untreated patients, as a propor-
tion of deficient patients were not on replacement; in the case of
HC and LT4 replacement, which is mandatory in ACTH and
TSH deficiencies, respectively, the effect of daily replacement
doses on relative mortality risk was also examined.
Materials and methods
Subjects
Following institutional approval (approval reference CAC-
04929-12), we performed a retrospective case note analysis of all
patients treated for NFPA at University Hospitals Birmingham
(UHB), United Kingdom, and Beaumont Hospital Dublin,
Republic of Ireland, between 1 January 1999 and 31 December
2014. Both newly diagnosed and existing follow-up patients
reviewed in the Pituitary Clinic for NFPA in both institutions
between the above dates were included in the analysis. UHB is a
tertiary centre for pituitary disease in the greater West Midlands
region of the UK, covering 16 regional referral centres and a
total population of 57 million. Beaumont Hospital in Dublin is
one of only two neurosurgical centres in the Republic of Ireland
and receives pituitary referrals from 20 regional hospitals,
encompassing a total population of 35 million. Data collection
was performed by trained staff in both study sites. Mortality
data on the Birmingham cohort were obtained via the UHB
electronic Clinical Portal, which is linked to both up-to-date GP
patient records and the Office of National Statistics. Vitality sta-
tus, date of death and cause of death, where applicable, of
patients in Dublin were determined via direct phone contact
with the patients’ primary care physician.
Evaluation of pituitary function
Pituitary function testing was performed 2 weeks pre-opera-
tively, 6 weeks postoperatively and annually thereafter in
patients with NFPA treated by surgery and/or RT in both study
centres. Baseline pituitary function testing was also performed
annually in patients who were treated by observation alone.
Overall pituitary function was defined as pituitary reserve at the
time of last clinic review before study exit (31 December 2014).
GH reserve was not routinely tested in either institution pre-
operatively; postoperative GH deficiency was defined by peak
GH levels <3 lg/l on insulin tolerance testing (ITT), or in the
absence of ITT (Birmingham patients pre-2002), by an insulin-
like growth factor-1 (IGF-1) level below age and sex-derived ref-
erence ranges in the setting of deficiencies of at least two other
pituitary hormones.20
A short synacthen test (SST) was performed at UHB pre-
operatively and 6 weeks postoperatively in patients undergoing
surgery; a SST was also performed annually in patients who had
undergone pituitary RT unless ACTH deficiency was already
confirmed. ACTH deficiency in UHB patients was defined as a
peak cortisol of <550 nmol/l after 250 lg of intramuscular
© 2016 The Authors. Clinical Endocrinology Published by John Wiley & Sons Ltd.
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cosyntropin (tetracosactide), according to locally derived norma-
tive data. ACTH reserve in the Dublin patient cohort was
assessed by measuring the response of cortisol to either the ITT
or the glucagon stimulation test (GST) pre-operatively and
6 weeks postoperatively, as previously described.21 Testing was
also performed annually in patients who underwent pituitary RT
unless ACTH deficiency was already confirmed. The normal cut-
off, derived from local normative data, was >500 nmol/l for ITT
and >450 nmol/l for GST. Due to the high prevalence of a false
‘fail’ rate (approximately 10%) on GST,22 subnormal cortisol
responses were confirmed by cosyntropin testing (250 lg) in
each case (normal >500 nmol/l based on local normative data);
patients were only considered ACTH deficient if they failed both
tests.
Low levels of free thyroxine (fT4; normal range 10–22 pmol/l)
in the presence of low or normal thyroid-stimulating hormone
(TSH; normal range 05–42 mIU/l), in patients without a pre-
existing history of thyroid disease, were deemed diagnostic of
thyrotroph dysfunction in both institutions. Gonadotropin (Gn)
deficiency was diagnosed in both institutions as follows: the
presence of amenorrhoea, low–normal Gonadotropins and low
oestradiol levels (<50 pmol/l) in premenopausal women; follicle-
stimulating hormone (FSH) and luteinizing hormone (LH) levels
below normal postmenopausal range (FSH < 30 U/l;
LH < 10 U/l, based on locally derived normative reference val-
ues) in postmenopausal women; and morning testosterone levels
<7 nmol/l (normal range 70–270 nmol/l) in the setting of low
or low–normal FSH and LH levels in men. Permanent diabetes
insipidus (DI) was diagnosed as the persistence of hypotonic
polyuria, responsive to desmopressin (DDAVP), at the 6-week
postoperative assessment; water deprivation testing was carried
out only in selected cases. Multiple hormone deficiencies were
defined by deficiency of at least two individual anterior pituitary
hormone axes. Panhypopituitarism was defined as the coexis-
tence of GH, Gn, ACTH and TSH deficiencies.
Statistical analysis
The Statistical Package for the Social Sciences (SPSS, Chicago,
IL, USA) version 22 was used for descriptive data analysis. All
data are expressed as median and range unless otherwise stated.
Independent samples t-tests or Mann–Whitney U-test were used
as appropriate for comparison between two groups. One-way
ANOVA with post hoc Tukey’s testing was used for multiple com-
parisons between different groups. STATA statistical software (Sta-
taCorp, College Station, TX, USA, version 14) was used for all
mortality analyses. Mortality was analysed using an internal sta-
tistical model to avoid the unmeasurable confounders that are
likely to exist between the study cohort and the background
general population.
A multivariable Cox regression model, with attained age as
the time-scale, and further adjusted for surgery, age at diagnosis,
attained age, sex and radiotherapy (RT) exposure, was used to
calculate relative risk of death according to pituitary function.
RT-treated patients entered the model for assessment of risk on
the date that RT was commenced. Treatment of GH and Gn
deficiencies was documented where appropriate, and relative risk
was compared to untreated patients with the corresponding hor-
mone deficiency. HC and LT4 dosages were included in the sta-
tistical model as time- and dose-dependent variables, as
previously described in the context of HC regimens in acrome-
galy.11 Relative risk was calculated for individual hormone defi-
ciencies compared to patients with intact function of the
corresponding pituitary axis. We also calculated the relative risk
of death across categories of increasing severity of pituitary fail-
ure at study exit. P-values were derived from likelihood ratio
tests. Kaplan–Meier survival curves for each hormone deficiency
were plotted by time since NFPA diagnosis. A two-sided P-value
of <005 was considered statistically significant.
Results
Patient characteristics
A total of 519 patients with NFPA were included in the study
(UHB n = 271, Beaumont n = 248, 622% males, Table 1).
Median patient age at diagnosis was 570 years (range 18–91).
Median length of follow-up in the combined cohort was
70 years (range 05–43 years). Birmingham and Dublin patients
did not differ significantly with regard to age at diagnosis or
duration of follow-up (P = 025 and 081, respectively). The
most common mode of NFPA presentation was visual dysfunc-
tion (482%), followed by headache/apoplexy (165%), incidental
(156%) and endocrine dysfunction (75%), with information on
presentation unavailable in 122%. On pre-operative magnetic
resonance imaging (MRI) of the pituitary, overt chiasmal com-
pression, cavernous sinus invasion or parasellar extension was
documented in 788% of patients; only 44% of patients had
intrasellar tumours. Of 519 patients, 470 underwent surgical
debulking of their tumour (TSS 808%), with the remainder
treated by observation alone; 121 patients (233%) had more
than one debulking surgery.
In total, 183 patients (353%) received pituitary RT, of whom
181 received conventional three-field fractionated irradiation. Of
the 183 irradiated patients, 80 (437%) received prophylactic RT
after their first operation; the remainder only received pituitary
RT at NFPA recurrence. Median RT dose was 45 Gy (range
45–504) administered in a median of 25 fractions (range
25–30). Two patients received stereotactic radiosurgery (SRS).
The rate of pituitary RT was higher in Birmingham than in
Dublin (424% vs 274%, P < 0001). A total of 289 patients had
surgery alone, 181 had surgery plus RT, and 2 patients were
treated with primary RT alone. The majority of resected
tumours had no stainable immunocontent (null cell tumour,
281 of 403 specimens, 697%). Silent gonadotrophinomas
(183%) and corticotrophinomas (55%) constituted the major-
ity of the remaining histological specimens.
In surgically treated patients, extrasellar tumour remnant was
observed on postoperative pituitary MRI in 208 of 414 available
scans (502%). NFPA regrowth was documented in 184 patients
(354%), with a median time to regrowth of 30 months (range
1–276). Regrowth occurred in 114 of 208 (548%) patients with
© 2016 The Authors. Clinical Endocrinology Published by John Wiley & Sons Ltd.
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extrasellar tumour remnant and 44 of 131 (335%) with intrasel-
lar tumour remnant compared to 6 of 75 (80%) patients with
no residual tumour or empty sella (P < 0001 for both).
Endocrine evaluation
The prevalence rates of GH, Gn, ACTH, TSH and antidiuretic
hormone (ADH) deficiencies in the total patient cohort at the end
of study follow-up are shown in Table 1. Complete endocrine data
were available in 493 patients. The rates of intact pituitary func-
tion, single hormone deficiency, multiple hormone deficiencies
and panhypopituitarism at study exit were 172% (n = 85), 99%
(n = 49), 249% (n = 123) and 479% (n = 236), respectively.
Panhypopituitarism was more common in RT-treated compared
to RT-na€ıve patients (562% vs 432%, P < 0001). GH, Gn,
ACTH and TSH deficiencies were all significantly more common
in irradiated compared to nonirradiated patients (Table 2).
Patients treated surgically had a higher rate of panhypopituitarism
compared to those managed with observation alone (504% vs
250%, P < 0001). Testosterone was prescribed in all male Gn-
deficient patients unless there was a clear contraindication such as
a history of prostate cancer. Oestrogen replacement was given to
all premenopausal Gn-deficient females. Testosterone and oestro-
gen replacement was prescribed in 798% and 215% of male and
female Gn-deficient patients, respectively. GH replacement was
prescribed for GH-deficient patients if they met the National Insti-
tute of Clinical Excellence criteria (323% of GH-deficient
patients).23 All ACTH- and TSH-deficient patients were treated
with HC and LT4, respectively.
Both pre-operative and overall (study exit) rates of panhy-
popituitarism were higher in male compared to female patients
(195% vs 91%, P = 0007, and 551% vs 361%, P < 0001,
respectively). The age profiles of patients across the spectrum of
increasing severity of hypopituitarism (intact, single deficiency,
multiple deficiencies and panhypopituitarism) were not statisti-
cally significantly different. In surgically treated patients, pitu-
itary function remained unchanged postoperatively in 712%,
with deterioration of pituitary function observed in 233% and
improvement in 55%.
Mortality
A total of 81 patient deaths (666% male) were recorded in the
combined cohort at the end of the study period. The median
age at death was 780 years (24–92); median time to death from
tumour diagnosis was 108 months (0–468). The number of
deaths did not differ significantly between men and women, or
between Dublin and Birmingham (Table 1). Data on cause of
death were available in 70 of 81 patients. Causes of death were
categorized as follows: cardiovascular (excluding cerebrovascular,
314%), cerebrovascular (229%), malignancy (171%), infection
(171%), respiratory (100%) and trauma (14%). The preva-
lence rates of GH, Gn, ACTH and TSH deficiencies were higher
in patients who later died compared to those still living
Table 1. Baseline characteristics of combined patient cohort (n = 519)
treated for NFPA at University Hospitals Birmingham (UHB) and
Beaumont Hospital Dublin between 1999 and 2014. Data presented as
number (%) unless otherwise stated. Hormonal status refers to pituitary
function at study exit
Treatment centre
Birmingham 271 (522)
Dublin 248 (478)
Age at diagnosis (years; median, range)
Male 57 (18–85)
Female 56 (20–91)
Gender distribution
Male 323 (622)
Female 196 (378)
Duration of follow-up (years; median, range)
Birmingham 60 (05–43)
Dublin 70 (05–35)
Presentation
Visual disturbance 250 (482)
Incidental 81 (156)
Headache 48 (92)
Endocrine dysfunction 39 (75)
Apoplexy 38 (73)
Unavailable 63 (121)
Treatment strategy
Surgery 470 (905)
(TSS n = 380; TCS n = 90)
Observation alone 49 (95)
NFPA immunohistochemistry (n = 470 resected tumours)
Null cell tumour 281 (697)
Gonadotrophinoma 74 (183)
Silent corticotrophinoma 22 (55)
Lactotroph 7 (17)
Somatotroph 6 (15)
Other/mixed immunostaining 13 (33)
Unavailable 67
RT 183 (353)
Birmingham 115 (424)
Dublin 68 (274)
Prophylactic adjuvant RT 80 (437)
RT at NFPA recurrence only 103 (563)
RT dose (Gy; median, range) 45 (45–504)
GH deficiency* 325 (659)
Gn deficiency* 355 (720)
ACTH deficiency* 318 (645)
TSH deficiency* 307 (623)
Diabetes insipidus* 51 (103)
HC daily dose (mg; median, range) 20 (5–50)
LT4 daily dose (mcg; median, range) 100 (25–225)
Tumour regrowth 184 (354)
Multiple surgeries 121 (233)
Deaths 81 (male n = 54) (156)
Centre Birmingham n = 40;
Dublin n = 41
Age at death (years; median, range) 78 (24–92)
ACTH, adrenocorticotropic hormone; DI, diabetes insipidus; GH,
growth hormone; Gn, gonadotropin; HC, hydrocortisone; LT4, levothy-
roxine; RT, radiotherapy; TCS, transcranial surgery; TSH, thyroid-stimu-
lating hormone; TSS, transsphenoidal surgery.
*Complete pituitary function data on 493 patients.
© 2016 The Authors. Clinical Endocrinology Published by John Wiley & Sons Ltd.
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(P < 0001 for all). Age at death was significantly lower in the
RT cohort (P = 003, Table 2). On internal analysis, after
correcting for surgery, age at diagnosis, sex and attained age,
RT-treated patients had a higher relative risk of death than non-
RT-treated patients (RR 162, 95% CI 101–260, P = 005,
Table 3). On cause-specific mortality analysis, RT-treated patients
had a higher relative risk of death from infection (RR 202, 95%
CI 103–397, P = 004). There was a trend towards a higher rela-
tive risk of cerebrovascular death in the RT group, but this asso-
ciation did not reach significance (RR 403, 076–2129,
P = 011). After correction for all associated pituitary hormone
deficiencies, RT was not independently associated with excess all-
cause mortality (RR 114, 95% CI 055–237, P = 073).
After correction for surgery, age at diagnosis, sex and attained
age, both ACTH and Gn deficiencies were independently associ-
ated with increased mortality (RR 256, 95% CI 110–596,
P = 001, and RR 226, 95% CI 115–447, P = 001, respectively,
Table 3). Relative risk of death was increased in those ACTH-
deficient patients taking total daily hydrocortisone doses of
30 mg or higher (RR 379, 95% CI 149–967, P < 001, P-
trend = 002, Table 3). Further subanalysis of Gn deficiency
according to gender, after additional adjustment for dysfunction
of all other pituitary hormone axes, revealed a significant associ-
ation with increased mortality in male patients only (RR 544,
95% CI 107–2769, P = 002). Male patients with untreated
hypogonadism had a trend towards a higher relative risk of
death than their treated counterparts, but this comparison did
not reach statistical significance (Table 4). No significant mortal-
ity difference was observed between treated and untreated Gn-
deficient women.
Although there was only a trend towards increased mortality
in TSH-deficient patients, relative risk of death was increased in
those patients taking <100 mcg daily dose of levothyroxine (RR
241, 95% CI 123–473, P = 001, Table 3). This association dis-
appeared at doses above 100 mcg daily (P = 086 and P = 045
for dosages ≥100 and >150 mcg, respectively, P-trend = 003).
GH-deficient patients were not at overall increased risk of death
compared to those with intact GH secretion (Fig. 1). However,
when considered separately, mortality risk was higher in
untreated compared to treated GH deficiency (Table 4).
There was a statistically significant linear trend towards
increased mortality risk across a spectrum of severity of pituitary
failure, with the highest risk observed in those with panhypopi-
tuitarism (P-trend = 004, Table 5).
Discussion
In this large cross-sectional study, we have performed a compre-
hensive analysis of the association between hypopituitarism and
mortality in NFPA. We have also examined the impact of
Table 2. Characteristics of RT- and non-RT-treated patients. Data
presented as number (%) unless otherwise stated. Hormonal status refers
to pituitary function at study exit
No RT (n = 336) RT (n = 183) P-value
Age at diagnosis
(years; median, range)
59 (20–91) 52 (18–79) <0001
Duration of follow-up
(years; median, range)
5 (05–35) 11 (05–43) <0001
GH deficiency* 199 (621) 126 (75) 002
Gn deficiency* 210 (662) 145 (823) <0001
ACTH deficiency* 185 (583) 133 (755) <0001
TSH deficiency* 172 (541) 135 (767) <0001
Diabetes insipidus* 39 (123) 12 (68) 006
Deaths 51 (152) 30 (163) 040
Age at death
(years; median, range)
79 (24–92) 72 (29–91) 003
ACTH, adrenocorticotropic hormone; DI, diabetes insipidus; GH,
growth hormone; Gn, gonadotropin; TCS, transcranial surgery; TSH,
thyroid-stimulating hormone; TSS, transsphenoidal surgery.
*Complete pituitary function data on 493 patients.
Table 3. Relative mortality risk (RR) calculated according to individual
pituitary hormone deficiencies and radiotherapy (RT) using a Cox
regression model
Pituitary
function RR (95% CI)*
P-
value RR (95% CI)†
P-
value
Growth hormone‡
Preserved (ref.)
Deficient 109 (055–216) 080 117 (059–233) 065
Gonadotropins‡
Preserved (ref.)
Deficient 265 (114–616) 001 256 (110–596) 001
ACTH‡
Preserved (ref.)
Deficient 228 (116–449) 001 226 (115–447) 001
TSH‡
Preserved (ref.)
Deficient 156 (095–257) 007 152 (092–252) 009
Vasopressin‡
Preserved (ref.)
Deficient 073 (029–185) 049 079 (031–203) 061
Radiotherapy
No (ref.)
Yes 162 (101–260) 005 – –
HC daily dose
0 mg (ref.)
5–20 mg 216 (077–606) 014 231 (082–649) 011
21–29 mg 163 (071–376) 025 179 (077–415) 018
≥30 mg 324 (130–811) 001 379 (149–967) <001
P-trend 005 002
LT4 daily dose
0 mcg (ref.)
<100 mcg 244 (124–479) 001 241 (123–473) 001
100–150 mcg 107 (052–220) 086 104 (050–215) 093
>150 mcg 062 (018–212) 045 061 (018–209) 043
P-trend 003 003
ACTH, adrenocorticotropic hormone; HC, hydrocortisone; LT4, levothy-
roxine; TSH, thyroid-stimulating hormone. All reference (ref.) RR val-
ues = 100.
*Internal Cox adjusted for surgery, age at diagnosis, attained age and
sex.
†Additionally adjusted for RT.
‡Complete pituitary function data on 493 patients.
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hormone replacement on relative risk of death; in the case of
HC and LT4, we have performed an in-depth analysis of the
effect of different daily replacement dosages on mortality. To
our knowledge, this is the first international collaborative study
of mortality in patients treated for NFPA, combining long-term
follow-up data from two large European cohorts, with a total
patient number in excess of 500. Internal statistical modelling
has identified ACTH and Gn deficiencies as conferring greater
than a two-fold increased relative risk of death compared to
those with intact axes. The vast majority of patients had detailed
annual pituitary function testing over a median follow-up period
of 7 years; many patients were followed for much longer. Com-
prehensive data on mortality status, tumour presentation, sur-
gery, histology, RT and hormone replacement were also
available on all patients. Our data convincingly reinforce the
dogma that risk of death increases in HC-treated patients in a
Table 4. Relative mortality risk in treated (Ref. 100) and untreated
gonadotropin and GH deficiency
Pituitary function RR (95% CI) P-value
Gonadotropin deficiency*
Male
Treated 100
Untreated 172 (071–416) 022
Female
Treated 100
Untreated 021 (003–277) 062
GH deficiency*,†
Treated 100
Untreated 581 (073–4623) 004
*Complete data on 493 patients. Internal Cox adjusted for surgery, RT,
age at diagnosis and attained age.
†Additionally adjusted for sex.
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Fig. 1 Kaplan–Meier curves (unadjusted) in the combined Dublin and Birmingham cohort according to hormonal status at study exit (a) Growth
hormone (GH) deficiency, (b) gonadotropin (Gn) deficiency, (c) adrenocorticotropic hormone (ACTH) deficiency and (d) thyroid-stimulating hormone
(TSH) deficiency. After adjustment, independent effects on increased mortality were observed only in ACTH and Gn deficiencies at study exit.
Table 5. Relative mortality risk (RR) according to severity of
hypopituitarism at study exit using a Cox regression model†
Severity of pituitary
dysfunction No. of deaths RR (95% CI)* P-value
Normal pituitary
function (ref.)
2/85 100 –
Single hormone deficiency 4/49 227 (039–1305) 036
Multiple hormone
deficiencies
23/123 313 (071–1386) 013
Panhypopituitarism 45/236 358 (084–1524) 008
*P-trend = 004.
†Calculated in 493 patients with complete pituitary function data at
study exit. Internal Cox adjusted for surgery, RT, age at diagnosis,
attained age and sex.
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dose-dependent fashion; conversely, patients with secondary
hypothyroidism may be chronically untreated, potentially con-
tributing to adverse cardiometabolic risk. We believe that NFPA
is the ‘purest’ biological model of pituitary disease within which
to consider the association between hypopituitarism and mortal-
ity, due to the exclusion of secretory pituitary tumours. Further-
more, by utilizing an internal statistical analysis, we have
attempted to avoid the potential confounding effect of unquan-
tifiable variables that differ between the study cohort and the
background population.
There has been extensive interest in the subject of hypopitu-
itarism and mortality in the last 25 years. Rosen and Bengtsson24
first documented premature mortality due to cardiovascular dis-
ease in a seminal publication in 1990. The study by Tomlinson
found a standardized mortality ratio (SMR) of 187 in hypopitu-
itary patients compared to the external population.16 However,
all patients in this study had hypopituitarism of varying severity,
and so comparison with an internal control group with normal
pituitary function was not possible. In our unselected cohort of
consecutive patients with NFPA, we found a highly significant
statistical linear trend between the severity of pituitary failure
and risk of premature death, with the highest risk observed in
those with panhypopituitarism. We included all NFPA patients
in the analysis, including a cohort of 49 patients who were man-
aged with observation alone. Both ACTH and Gn deficiencies
predicted mortality in our study. We did not find a significant
association between GH, TSH or vasopressin deficiencies and
risk of death in our NFPA cohort. However, when analysed sep-
arately, patients with treated GH deficiency clearly had a survival
benefit over their untreated counterparts, with a fivefold higher
relative mortality risk in the untreated group. Adult-onset GH
deficiency has been associated with increased mortality in some
but not all studies;16,19,25 of these studies, van Bunderen et al.19
found that treatment with GH restored cardiovascular risk to
normal in male, but not in female, patients. Our data also sup-
port our hypothesis that the cumulative effect of dysfunction of
multiple hormonal axes may confer an increased relative risk of
death, even in the absence of independent contributions from
individual axes. This observation may be attributable to factors
such as inadequate or overzealous hormone replacement, medi-
cation interaction or other as yet undefined physiological phe-
nomena.
Our observation of increased mortality in ACTH-deficient
NFPA patients mirrors data from patients with acromegaly, and
in other cohorts with pituitary dysfunction.11,26 ACTH defi-
ciency leads to hypocortisolism during acute illness,27 with a sig-
nificant risk of life-threatening adrenal crisis. It is also intimately
associated with the adverse metabolic effects of chronic supra-
physiological glucocorticoid replacement.18,28 We have shown
that mortality risk is increased almost fourfold in patients taking
total daily hydrocortisone doses of 30 mg or higher. Zueger
et al.18 also found increased mortality with higher hydrocorti-
sone dosages in ACTH-deficient NFPA patients in a Swiss study;
this finding was consistent for both total and weight-adjusted
hydrocortisone doses, and the same associations have been
observed in acromegaly.11 Interestingly, we found that daily
replacement doses of LT4 below 100 mcg in TSH-deficient
patients were associated with a higher mortality risk. To our
knowledge, this unexpected observation has not been demon-
strated previously in secondary hypothyroidism. Optimal treat-
ment of TSH deficiency is limited by the absence of a reliable
biomarker of adequate replacement, as LT4 doses cannot be
titrated according to TSH levels in pituitary failure. These data
support the clinical suspicion that many pituitary patients with
secondary hypothyroidism are chronically undertreated.29
Gonadotropin deficiency conferred the highest relative risk of
death of all pituitary axis deficiencies in our study. This finding
mirrors results from the Tomlinson study, where untreated Gn
deficiency in the NFPA subgroup was associated with an
increased risk of death (SMR 285); this risk was normalized by
hormone replacement.16 Subgroup analysis in our Gn-deficient
cohort found that this association was only significant in men;
hypogonadal males had a greater than fivefold increased risk of
mortality compared to the eugonadal reference cohort. Male
hypogonadism is associated with dyslipidaemia, hypertension,
insulin resistance and atherosclerosis,30,31 but it remains divisive
whether is an independent risk factor or simply a surrogate mar-
ker for underlying metabolic disease.32 Low testosterone is also
associated with increased mortality in unselected cohorts with-
out evidence of pituitary disease.33,34 In our study, hypogonadal
men who were not treated with testosterone had a trend towards
a higher relative risk of death; however, the statistical power of
this analysis is likely to be limited by relatively small numbers of
untreated hypogonadal men (215%). Equally, no mortality ben-
efit or risk was conferred by oestrogen replacement in our study,
but, once again, this analysis is likely to be underpowered; only
20% of Gn-deficient females were treated with oestrogen, and
only a very small number of deaths were observed in pre-
menopausal females.
Other mortality studies in NFPA patients with hypopitu-
itarism have shown conflicting results to date. A recent study of
546 patients from Oxford found increased overall mortality on
external analysis (SMR 3.8) in a series of 546 patients operated
for NFPA.35 Only young age at diagnosis was predictive of pre-
mature death on multivariate analysis, with no independent con-
tribution from individual pituitary hormone deficiencies.
However, the study did not include patients with microadeno-
mas, and only included surgically treated patients, which is likely
to reduce the proportion of patients with normal pituitary func-
tion to include as an internal comparator group. Another Swed-
ish population-based study of over 2700 patients with NFPA
recently showed premature mortality only in female NFPA
patients with hypopituitarism or diabetes insipidus.14 The overall
SMR for patients with hypopituitarism was similar to the back-
ground population, but detailed data on pituitary function were
not available to the authors.
Patients who underwent pituitary irradiation in our study had
a significantly increased risk of death (RR 162). The median age
at death in RT-treated patients was 7 years younger than in the
RT-na€ıve cohort. However, after correction for pituitary dys-
function, this association was no longer significant, suggesting
that the observed increase in premature mortality is mediated by
© 2016 The Authors. Clinical Endocrinology Published by John Wiley & Sons Ltd.
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RT-induced hypopituitarism rather than an independent effect
of RT itself. These data are consistent with findings from Tom-
linson and other older studies,16,36 as well as the more recent
van Varsseveld and Oxford studies.17,35 There was a trend
towards an increased risk of cerebrovascular death compared to
nonirradiated patients, but this did not reach statistical signifi-
cance. Intriguingly, RT-treated patients had a twofold increased
risk of death from infection. This association is likely to be
mediated by RT-induced hypopituitarism. This is particularly
true in those with ACTH deficiency, who are at significantly
increased risk of succumbing to infection-induced adrenal cri-
sis.37 Whether RT is independently associated with premature
mortality, or whether these associations are driven purely by
hypopituitarism, will remain a matter of debate. It is increas-
ingly clear, however, that conventional three-field fractionated
pituitary RT is associated, directly or indirectly, with morbidity
and mortality. Long-term data on SRS are sparse, however;
recent studies suggest reduced neurotoxicity, although the preva-
lence of hypopituitarism may still be relatively high.38
Our study has a number of limitations. Pituitary function data,
as in most studies on hypopituitarism, are presented as a snapshot
at study exit, rather than as a dynamic variable throughout follow-
up. Secondly, there is a degree of heterogeneity in the evaluation
of pituitary function between the two centres. In Birmingham, a
cosyntropin test was used for assessment of ACTH reserve, while
Dublin patients underwent ITT, or GST followed by cosyntropin
test where appropriate. While controversy exists over the most
appropriate test for secondary adrenal insufficiency in pituitary
disease, recent data suggest good correlation between distinct test-
ing methods, as long as unique normative cut-off levels have been
determined for each (as was the case in both study centres).39 A
policy of dynamic testing of GH reserve was not universally
applied to the Birmingham cohort pre-2002. However, IGF-1
levels below age and sex-derived reference ranges, in the setting of
deficiencies of at least two other pituitary hormones, have been
validated as a reasonable diagnostic alternative in cases where ITT
is not available.20,40 Although desirable, complete homogeneity of
dynamic testing strategies is not realistic when combining pitu-
itary function data from different centres. These limitations
notwithstanding, we believe that pituitary function and mortality
data have been accurately collated on all patients in both cohorts.
The predominant strength of this study lies in the size of the pop-
ulation studied, which comprises in excess of 500 patients. The
novelty of our work is underpinned by the combination of in-
depth phenotyping of pituitary function with comprehensive data
on treatment of multiple pituitary hormone deficiencies. This has
facilitated robust analysis of the associations between hypopitu-
itarism, under- or overreplacement of deficient hormones, and,
ultimately, risk of death.
In summary, in this large cohort of 519 NFPA patients derived
from tertiary neurosurgical centres in the UK and Republic of Ire-
land, we have identified independent associations of both ACTH
and Gn deficiencies with mortality. Whether individual hormone
deficiencies themselves, or more complex treatment-associated
factors, underpin these relationships requires further work, partic-
ularly in the context of male hypogonadism. Excessive HC
replacement, coupled with suboptimal treatment of central
hypothyroidism, may contribute further to the adverse car-
diometabolic milieu in hypopituitary NFPA patients. Whilst pitu-
itary RT is also associated with an increased relative risk of death
in NFPA, the connection with increased mortality may be attribu-
table simply to the high prevalence of hypopituitarism in irradi-
ated patients. We have also shown that mortality risk in patients
treated for NFPA increases in a linear fashion across a spectrum of
pituitary failure. This suggests a cumulative contribution of multi-
ple hormone deficiencies, which is potentially greater than the
sum of individual risk.
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